Please assess the completion status of the following clinical trial:

Trial Title: Placebo Controled Clinical Trial Using Topiramate To Treat Posttraumatic Stress Disorder (PTSD) Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient, male and female 18 to 60 yrs old~* PTSD diagnostic according to DSM-IV criteria~* Patients who agree to receive diagnostic after SCID I application by a trained psychiatrist~* Sexually active female patients who agree to use contraceptive~* Patients who agree to sign the IRB approved informed consent~Exclusion Criteria:~* Patients who have schizophrenic disorder, delusional, psychotic depression, schizo-affective, bipolar and dependence to psychoactive substance disorders~* Patients who have clinical disorders not compensated, which require clinical treatment as priority~* Pregnancy~* Previous renal calculosis history~* Being under antidepressant, or other psychotropic medications~* BMI under 20.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Topiramate (Type: EXPERIMENTAL): patients receiving the active drug: topiramate
- Placebo Control group (Type: PLACEBO_COMPARATOR): patients received pills content placebo, that were identical to the pills content active drug

Based on this trial design, predict the completion outcome and termination type (if applicable).